Loading clinical trials...

Moving Foward With Myeloma (MFM) | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGNA

Moving Foward With Myeloma (MFM)

Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma

NCT07236502•Medical College of Wisconsin

Summary

The purpose of this project is to evaluate the impact of a 16-week lifestyle program that promotes changes in eating and exercise patterns. The main questions the study will answer are: Do improvements in eating and exercise patterns lead to improved physical function, quality of life and blood biomarkers of biologial aging among individuals with multiple myeloma? Participants will complete study activities 3-4 times during the study. 1. In-person assessment to measure physical function, height/weight, body composition, and includes a blood draw 2. Surveys completed online or on paper at home

Detailed Description

The study uses a randomized, waitlist control design. Following baseline data collection, participants will be randomized to either the immediate lifestyle intervention group or the waitlist control group. Those who are randomized to the waitlist control group will receive the intervention after the 16-week data collection time point.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Adult (≥ 18 years)
•2. Diagnosed with MM at least one year prior to study enrollment
•3. Has access to a cell phone
•4. Be deemed "clinically stable" by their physician guided by the following:
•1. no near-term changes in planned myeloma-directed therapy anticipated. (e.g., patient who is 3 months from autologous stem cell transplant just starting on maintenance lenalidomide is eligible since maintenance is planned therapy following transplant)
•2. no new significant myeloma symptoms (e.g., fractures) meriting changes in anti-neoplastic therapies; AND
•3. stable performance status (ECOG 0-2)
•5. No reports of severe pain \> Grade 3 \[defined by the NCI CTCAE as tumor, neurologic, bone, or other pain interfering with self-care ADLs (bathing, dressing, toileting, continence, feeding)\].
•6. Able to participate in moderate PA and strength training per clinician approval and confirmed by participant
•7. Able to understand and willing to sign a written informed consent document
+1 more criteria

Exclusion Criteria

•1. Individuals with \<6 months of life anticipated, coexistent amyloidosis, and/or receiving appetite stimulants will not be approached
•2. Fully adherent to the ACS nutrition and physical activity guidelines
•3. Currently pregnant or lactating, or anticipating pregnancy
•4. On another interventional clinical trial that precludes co-enrollment
•5. Psychiatric or other clinical conditions that preclude study compliance
•6. Other important medical or safety considerations at the discretion of the investigator(s) and/or approving clinician

Locations (2)

Loyola University Chicago

Maywood, Illinois, United States

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Key Dates

Start Date

January 30, 2026

Primary Completion Date

December 15, 2029

Completion Date

February 28, 2030

Last Updated

January 12, 2026

Enrollment

184

ESTIMATED participants

Conditions

Multiple Myeloma (MM)

Interventions

Immediate intervention

BEHAVIORAL

Waitlist

OTHER

Contacts

Melinda Stolley, PhD

CONTACT

(312)735-6044 mstolley@mcw.edu

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

NCT07280013

Multiple Myeloma (MM)

View study

RECRUITINGPHASE1

Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma

NCT07333430

Relapsed/Refractory Multiple Myeloma (MM)

View study

RECRUITING

A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease Recurrence

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 12, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Moving Foward With Myeloma (MFM)

Inclusion Criteria

Exclusion Criteria

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma

A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease Recurrence

Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.

A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Rehabilitation Management for Patients with Multiple Myeloma